Clinical trials: Pancreatic Metastasis
Pancreatic Adenocarcinoma
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
This study is a prospective, open-label, randomized controlled trial that enrolled previously untreated patients with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT06789679
- Testing
- Gemcitabine, albumin-bound paclitaxel, S-1, Gemcitabine, albumin-bound paclitaxel
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreatic Cancer
Huachansu & Gemcitabine in Pancreatic Cancer
This protocol is part of a larger grant funded by the NCI to create an international research center to study traditional Chinese medicine (TCM).
- Trial name
- NCT00837239
- Testing
- Gemcitabine, HuaChanSu
- Where
- China
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
This clinical trial tests the safety, side effects, best dose and feasibility of using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography for the imaging of patients with PSCA-expressing pancreatic cancer that has spread…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT07608627
- Testing
- Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Pancreatic Cancer
3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00078975
- Testing
- gemcitabine hydrochloride, triapine
- Where
- 4 sites in Canada
- Volunteers
- 26 people
- Sponsor
- University Health Network, Toronto
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where…
- Conditions
- Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic
- Trial name
- NCT05074472
- Testing
- ZB131
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- ZielBio, Inc.
Neoplasms Pancreatic
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
This study is comparing two combinations of chemotherapy treatments in patients with metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half will receive AG.
- Trial name
- NCT04151277
- Testing
- FOLFOX-A, Gemcitabe and Abraxane, G-CSF
- Where
- 30 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Judith Dixon-Hughes
Metastatic Pancreatic Ductal Adenocarcinoma
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02583477
- Testing
- MEDI4736 in combination with nab-paclitaxel and gemcitabine, MEDI4736 in combination with AZD5069
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in treating patients with…
- Trial name
- PANTER (NCT00964171)
- Testing
- Efavirenz 600mg
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Institut Bergonié
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX
Neutropenia, a decrease in the number of neutrophils, a type of white blood cell, due to the myelosuppressive effects of chemotherapeutic drugs, is a frequent occurrence in patients receiving anticancer drug therapy, which…
- Trial name
- NCT06353581
- Testing
- Neulapeg, Control
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Yonsei University
Lung Neoplasms, Pancreatic Neoplasms
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
This is a combined prospective and retrospective observational study aiming to validate a highly sensitive and specific blood-based method for the early diagnosis and post-treatment monitoring of multiple cancers.
- Conditions
- Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms
- Trial name
- NCT07035587
- Testing
- Serial Blood Sampling for Molecular Profiling, One-Time Blood Sampling for Molecular Profiling
- Where
- South Korea
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Pancreatic Adenocarcinoma, Metastatic
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
- Trial name
- VIRAGE (NCT05673811)
- Testing
- Nab-paclitaxel, Gemcitabine, VCN-01
- Where
- 17 sites in United States, Spain
- Volunteers
- 112 people
- Sponsor
- Theriva Biologics SL
Metastatic Pancreatic Cancer
Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
To evaluate the combination of ABI-007 with gemcitabine or with LV5FU2.
- Trial name
- AFUGEM (NCT01964534)
- Testing
- ABI-007, Gemcitabine, simplified LV5FU2
- Where
- 15 sites in France
- Volunteers
- 114 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma (PDAC)
- Trial name
- NCT04046887
- Testing
- Lonsurf, Gemcitabine, Nab-Paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Patrick Joseph Loehrer Sr.
Metastatic Pancreatic Adenocarcinoma
A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
This is a phase 1b, multi-center, open label, randomized study to evaluate the safety and feasibility of administering metformin with or without rapamycin after disease stabilization on chemotherapy in subjects with metastatic…
- Trial name
- NCT02048384
- Testing
- metformin alone (Arm A), metformin (Arm B), rapamycin (Arm B)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Neoplasm
DDP ip Combined With AG in PDAC With Peritoneal Metastasis
intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
- Trial name
- NCT05222204
- Testing
- intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel
- Where
- 2 sites in China
- Volunteers
- 91 people
- Sponsor
- Fudan University
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
- Trial name
- STELLAR-311 (NCT06943755)
- Testing
- Zanzalintinib, Everolimus
- Where
- 135 sites in United States, Australia and 16 more
- Volunteers
- 440 people
- Sponsor
- Exelixis
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer.
- Trial name
- NCT01472198
- Testing
- Simtuzumab, Gemcitabine
- Where
- 57 sites in United States, Russia
- Volunteers
- 250 people
- Sponsor
- Gilead Sciences
Pancreatic Cancer
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1701 in combination with gemcitabine and albumin paclitaxel in first-line treatment of subjects with advanced/metastatic pancreatic cancer, and…
- Trial name
- NCT04624217
- Testing
- SHR-1701
- Where
- 2 sites in China
- Volunteers
- 56 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Pancreatic Cancer
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
To learn if the investigational study drug, adagrasib (also called MRTX849), can help to control pancreatic cancer that has a KRAS G12 mutation. The safety and possible effects of adagrasib will also be studied.
- Trial name
- NCT05634525
- Testing
- MRTX849
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.